News - Immunologicals, Oncology

Filter

Current filters:

ImmunologicalsOncology

Popular Filters

1 to 25 of 30 results

Ligand in licensing deal with TG Thera for IRAK-4 inhibitor program

Ligand in licensing deal with TG Thera for IRAK-4 inhibitor program

24-06-2014

US drugmaker Ligand Pharmaceuticals has signed an exclusive global license accord with TG Therapeutics…

ImmunologicalsLicensingLigand PharmaceuticalsOncologyPharmaceuticalTG Therapeutics

MorphoSys and Merck Serono collaborate on immuno-oncology

MorphoSys and Merck Serono collaborate on immuno-oncology

12-06-2014

German companies MorphoSys and Merck KGaA unit Merck Serono today announced the signing of an agreement…

BiotechnologyCancer therapyHealth Medical PharmaHuman antibody technologiesImmune systemImmunologicalsLeaderLicensingMerck KGaAMerck SeronoMorphoSysOncologyResearch

Eisai's R&D unit Kan Research Institute starts full-scale operation at new facility

27-05-2014

Japanese drug major Eisai Co says that its R&D subsidiary KAN Research Institute held a dedication ceremony…

BiotechnologyEisaiImmunologicalsJapanKan Research InstituteNeurologicalOncologyResearch

AnaptysBio and Tesaro team up in $340 million oncology deal

14-03-2014

Therapeutic antibody discoverer AnaptysBio announced a strategic immuno-oncology collaboration with fellow…

AnaptysBioBiotechnologyImmunologicalsLicensingOncologyTesaro

Scancell granted orphan drug designation for melanoma drug

Scancell granted orphan drug designation for melanoma drug

17-02-2014

UK-based immunotherapy company Scancell has been granted orphan drug designation for its SCIB1 ImmunoBody…

ImmunologicalsOncologyPharmaceuticalRegulationScancellSCIB1UKUSA

AbbVie to spend $320 million to establish Singapore manufacturing presence

AbbVie to spend $320 million to establish Singapore manufacturing presence

06-02-2014

US drugmaker AbbVie says it plans to invest $320 million to establish operations in Singapore for small…

AbbVieAsia-PacificImmunologicalsOncologyPharmaceuticalProduction

Medigene’s buy of Trianta is “lucrative move” say analysts

31-01-2014

Medigene’s 4 million euro ($5.5 million) purchase of fellow German company Trianta Immunotherapies…

FinancialImmunologicalsMedigeneMergers & AcquisitionsOncologyPharmaceuticalTrianta ImmunotherapiesUSA

Janssen in-licenses rights to novel cancer therapy from CSL

Janssen in-licenses rights to novel cancer therapy from CSL

05-12-2013

Australian blood products and vaccine maker CSL Ltd has entered into an agreement with Janssen Biotech,…

BiotechnologyCSL LimitedHematologyImmunologicalsJanssen BiotechJohnson & JohnsonLicensingOncology

Roche and immatics ink mega-million cancer vaccine and immunotherapy deal

Roche and immatics ink mega-million cancer vaccine and immunotherapy deal

13-11-2013

Germany’s privately-held immatics biotechnologies GmbH and Swiss drug major Roche have entered into…

BiotechnologyIMA942immatics biotechnologiesImmunologicalsOncologyRocheVaccines

Gliknik enters licensing agreement with Pfizer

30-09-2013

Gliknik has entered into an exclusive worldwide licensing agreement with Pfizer for GL-2045, which is…

BiotechnologyGliknikImmunologicalsLicensingNorth AmericaOncologyPfizer

Ablynx and Merck Serono expand collaboration on Nanobodies

Ablynx and Merck Serono expand collaboration on Nanobodies

26-09-2013

Ablynx and Merck Serono have expanded their collaboration on the co-discovery and co-development of Nanobodies.

AblynxBiotechnologyEuropeImmunologicalsMerck SeronoNeurologicalOncologyResearch

Swedish researcher report on unexpected use of former cancer drug

29-08-2013

Researchers at Sweden's Lund University have unexpectedly discovered that an old cancer drug - zebularine…

ImmunologicalsOncologyPharmaceuticalResearchzebularine

US firms establish strategic partnership around biosimilars

06-08-2013

Privately-held Oncobiologics has formed a broad strategic partnership with fellow USA-based inVentiv…

AvastinBiotechnologyErbituxGenericsHerceptinHumiraImmunologicalsinVentive HealthOncobiologicsOncologyProductionResearchRituxan

Merck Serono sets up new platform for cancer therapies innovation

26-06-2013

Merck Serono, the biopharmaceutical division of Germany's Merck KGaA (MRK: DE) says it has created a…

BiotechnologyImmunologicalsMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

Additional indications in Japan for Roche's Avastin and Astellas' Prograf

17-06-2013

Swiss drug major Roche (ROG: SIX) says that the Japanese Ministry of Health, Labor and Welfare (MHLW)…

Asia-PacificAstellas PharmaAvastinBiotechnologyImmunologicalsOncologyPharmaceuticalPrografRegulationRoche

Hikma in-licenses inhaled insulin for MENA; Advaxis and FusionVax Asia deal

23-04-2013

Jordan-based Hikma Pharmaceuticals (LSE: HIK) has signed a licensing and distribution agreement with…

AdvaxisADXS-HPVAsia-PacificDance 01Dance BiopharmDiabetesFusionVaxHikma PharmaceuticalsImmunologicalsLicensingOncologyPharmaceuticalRest of the World

Resverlogix to spin-out RVX Thera to unlock epigenetics platform value

10-04-2013

Canadian drugmaker Resverlogix (TSX:RVX), which is exploring a sale, says that its board of directors…

ApolipoproteinBiotechnologyImmunologicalsMergers & AcquisitionsOncologyResverlogixRVX TherapeuticsRVX-208

Bayer expands collaboration with DKFZ into immunotherapy

10-04-2013

German drug major Bayer (BAYN: DE) said revealed this morning that it will extend if already successful…

BayerImmunologicalsOncologyPharmaceuticalResearch

Aduro BioTech buys all GVAX assets from BioSante; Aspen in talks to buy Merck unit

05-02-2013

Aduro BioTech, a privately-held, US venture capital backed biotechnology company, says it has acquired…

Aduro BioTechAspen PharmacareBioSante PharmaceuticalsBiotechnologyGenericsGVAXImmunologicalsMerck & CoMergers & AcquisitionsOncologyVaccines

European therapeutic MAbs market to reach over $42 billion in 2018, says F&S

10-10-2012

Efficient resource to therapy of complex disorders with lesser side effects has accelerated growth of…

BiotechnologyImmunologicalsInflammatory diseasesMarkets & MarketingOncologyPharmaceuticalResearch

TG Thera in up to $250 million deal with Rhizen

17-08-2012

US development stage company TG Therapeutics (GTX:OTC B) has entered into an exclusive global agreement…

BiotechnologyImmunologicalsLicensingOncologyRhizen PharmaceuticalsTG TherapeuticsTGR-1202

Cell Therapeutics to acquire pacritinib, a potential myelofibrosis drug

20-04-2012

US biotech firm Cell Therapeutics (Nasdaq and MTA: CTIC) and Singapore-based S*BIO Pte have entered into…

BiotechnologyCell TherapeuticsImmunologicalsLicensingOncologypacritinibS*BIO

1 to 25 of 30 results

Back to top